Iron increases the susceptibility of multiple myeloma cells to bortezomib

Alessandro Campanella, Paolo Santambrogio, Francesca Fontana, Michela Frenquelli, Simone Cenci, Magda Marcatti, Roberto Sitia, Giovanni Tonon, Clara Camaschella

Research output: Contribution to journalArticlepeer-review

Abstract

Multiple myeloma is a malignant still incurable plasma cell disorder. Pharmacological treatment based on proteasome inhibition has improved patient outcome; however, bortezomib-resistance remains a major clinical problem. Inhibition of proteasome functionality affects cellular iron homeostasis and iron is a potent inducer of reactive oxygen species and cell death, unless safely stored in ferritin. We explored the potential role of iron in bortezomib-resistance. We analyzed iron proteins, oxidative status and cell viability in 7 multiple myeloma cell lines and in plasma cells from 5 patients. Cells were treated with increasing bortezomib concentrations with or without iron supplementation. We reduced ferritin levels by both shRNA technology and by drug-induced iron starvation. Multiple myeloma cell lines are characterized by distinct ferritin levels, which directly correlate with bortezomib resistance. We observed that iron supplementation upon bortezomib promotes protein oxidation and cell death, and that iron toxicity inversely correlates with basal ferritin levels. Bortezomib prevents ferritin upregulation in response to iron, thus limiting the ability to buffer reactive oxygen species. Consequently, reduction of basal ferritin levels increases both bortezomib sensitivity and iron toxicity. In patients' cells, we confirmed that bortezomib prevents ferritin increase, that iron supplementation upon bortezomib increases cell death and that ferritin reduction overcomes bortezomib resistance. Bortezomib affects iron homeostasis, sensitizing cells to oxidative damage. Modulation of iron status is a strategy worth exploring to improve the efficacy of proteasome inhibition therapies.

Original languageEnglish
Pages (from-to)971-979
Number of pages9
JournalHaematologica
Volume98
Issue number6
DOIs
Publication statusPublished - 2013

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Iron increases the susceptibility of multiple myeloma cells to bortezomib'. Together they form a unique fingerprint.

Cite this